Evidence map›Paper›PMID 34845849›Full record

ArticleClinical and translational medicine2021

T cell landscape and dynamics in immunoglobulin light chain amyloidosis before and after daratumumab-based therapy.

Yujia Wang, Lushuang Xu, Weijia Zhao, Xiaojie Chen, Lei Wen, Wenbing Duan, Xiao-Juan Yu, Fu- De Zhou, Yang Liu, Jie Hao and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.1field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Yujia WangDepartment of Immunology, School of Basic Medical Sciences, Peking University. NHC Key Laboratory of Medical Immunology (Peking University), Beijing, China.
Lushuang XuDepartment of Immunology, School of Basic Medical Sciences, Peking University. NHC Key Laboratory of Medical Immunology (Peking University), Beijing, China.
Weijia ZhaoDepartment of Immunology, School of Basic Medical Sciences, Peking University. NHC Key Laboratory of Medical Immunology (Peking University), Beijing, China.
Xiaojie ChenBasenByte Biotechnology Co., Ltd., Beijing, China.
Lei WenBeijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University People's Hospital & Institute of Hematology, Beijing, China.
Wenbing DuanBeijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University People's Hospital & Institute of Hematology, Beijing, China.
Xiao-Juan YuRenal Division, Department of Medicine, Institute of Nephrology, Peking University First Hospital, & Renal Pathology Center, Peking University, Beijing, China.
Fu- De ZhouRenal Division, Department of Medicine, Institute of Nephrology, Peking University First Hospital, & Renal Pathology Center, Peking University, Beijing, China.
Yang LiuBeijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University People's Hospital & Institute of Hematology, Beijing, China.
Jie HaoDepartment of Immunology, School of Basic Medical Sciences, Peking University. NHC Key Laboratory of Medical Immunology (Peking University), Beijing, China.
Xiaojun HuangBeijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University People's Hospital & Institute of Hematology, Beijing, China.
Jin LuBeijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University People's Hospital & Institute of Hematology, Beijing, China.
Qing GeDepartment of Immunology, School of Basic Medical Sciences, Peking University. NHC Key Laboratory of Medical Immunology (Peking University), Beijing, China.ORCID 0000-0002-6231-4545
Peking University · CNMinistry of Education of the People's Republic of China · CNBeijing VDJBio (China) · CN

Funding

Beijing Municipal Science and Technology Commission 191100007619018Beijing Natural Science Foundation 7202079Foundation for Innovative Research Groups of the National Natural Science Foundation of China 81621001National Key Research and Development Program of China 2017YFA0104500National Natural Science Foundation of China 31671244National Natural Science Foundation of China 31872734National Natural Science Foundation of China 32070897National Natural Science Foundation of China 8217010424National Natural Science Foundation of China 91853202Non-Profit Central Research Institute Fund of Chinese Academy of Medical Sciences 2018PT31039Open Funding Project of National Key Laboratory of Human Factors Engineering 6142222200105
6 · The paper itself

Abstract

Amyloid light-chain (AL) is characterized by the presence of small, poorly proliferating plasma cell clones with the production and deposition of light chains into tissues. T cell changes within the tumour microenvironment in AL are poorly understood. By sequencing at a single-cell level of CD3

Indexed as

Antibodies, MonoclonalHumansImmunoglobulin Light-chain AmyloidosisPlasma CellsT-LymphocytesAntibodies, Monoclonaldaratumumabbone marrow resident memory T cellsdaratumumabimmunoglobulin light chain amyloidosissingle-cell RNA sequencingT cells

Identifiers

PMID34845849
PMCPMC8630449
OpenAlexW3216141366

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.